Clark Amy S, Vahdat Linda T
Division of Hematology/Medical Oncology, Weill Medical College of Cornell University, New York.
Support Cancer Ther. 2004 Jul 1;1(4):213-8. doi: 10.3816/SCT.2004.n.013.
Palmar-plantar erythrodysesthesia, or hand-foot syndrome (HFS), is emerging as a common, dose-dependent toxicity of many newer chemotherapy drugs. Frequently, HFS is a dose-limiting toxicity requiring discontinuation of treatment, chemotherapy dose reductions, or delays. The spectrum of symptoms of HFS can be mild, with erythema of the distal extremities, or it can be severe enough to interfere with activities of daily living. Although the exact mechanism is unknown, there are several approaches to ameliorating the symptoms of this complication. These include antiinflammatory agents, vitamin products, and peripheral vasoconstricting agents.
掌跖红斑感觉异常，即手足综合征（HFS），正逐渐成为许多新型化疗药物常见的剂量依赖性毒性反应。HFS常常是一种剂量限制性毒性反应，需要中断治疗、减少化疗剂量或延迟化疗。HFS的症状范围可以很轻微，仅表现为远端肢体红斑，也可能严重到干扰日常生活活动。尽管确切机制尚不清楚，但有几种方法可改善这种并发症的症状。这些方法包括抗炎药、维生素类产品和外周血管收缩剂。
